Related Experiment Video
Updated: May 23, 2026
11:50
Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit
Published on: January 7, 2020
Chemotherapy in newborns and preterm babies
1Newcastle Cancer Centre at the Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne NE2 4H, UK.
Seminars in Fetal & Neonatal Medicine
|April 3, 2012
Summary
Determining pediatric cancer drug doses is challenging due to infants
Area of Science:
- Pediatric Oncology
- Clinical Pharmacology
- Developmental Physiology
Background:
- Dosing regimens for infants and young children with cancer pose significant challenges.
- Dose reductions for chemotherapeutics are common, but their appropriateness is uncertain due to limited pharmacokinetic data in this population.
- Significant physiological changes occur during early development, impacting drug disposition, response, and toxicity.
Purpose of the Study:
- To review the developmental physiology of preterm babies and infants.
- To analyze the impact of physiological changes on drug disposition, clinical response, and toxicity of anticancer drugs.
- To compare dose reductions for anticancer drugs across tumor types and clinical protocols, highlighting pharmacokinetic differences.
Main Methods:
- Review of existing literature on infant physiology and pharmacokinetics.
- Comparison of dose reduction strategies for key anticancer agents.
- Analysis of available pharmacokinetic data in infant populations versus older children.
Main Results:
- Significant physiological changes in infants impact drug pharmacokinetics.
- Limited pharmacokinetic data exist for many anticancer drugs in infants.
- Variability in drug response and toxicity is observed, influenced by developmental stage.
Conclusions:
- Appropriate dosing for pediatric cancer patients requires further investigation.
- Population pharmacokinetic studies are crucial for optimizing drug regimens in infants.
- Addressing formulation and ethical challenges is necessary for conducting pediatric pharmacology research.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...